A Phase 1, Two Period Crossover Study to Assess the Effect of a High Fat Meal on the Pharmacokinetics of Surufatinib in Healthy Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- AUC (0-t) of Surufatinib
研究概览
简要总结
This study will be a 2-period study conducted with 26 healthy male or female subjects. Subjects will be randomly assigned to either receive a single dose of surufatinib with food in period 1, then without food in period 2, or vice-versa.
详细描述
This study will be a single center, open label, randomized crossover, 2-period study conducted with 26 healthy male or female subjects. Subjects will be randomly assigned to 1 of the 2 possible treatment sequences as follows:
- Fed/Fasted: surufatinib with food on Day 1 and surufatinib without food on Day 8
- Fasting/Fed: surufatinib without food on Day 1 and surufatinib with food on Day 8
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Non-smoking, healthy male or female between the ages of 18 and 55 years old inclusive).
- •Body mass index (BMI) > 18 and ≤ 29 kg/m
- •Females must be of non-childbearing potential, or of childbearing potential and agree to use a medically acceptable method of contraception.
- •Males who have not had a successful vasectomy and are partners of women of childbearing potential must use, or their partners must use, a highly effective method of contraception starting for at least one menstrual cycle prior to and throughout the entire study period, and for 2 weeks after the last dose of study drug. Those with partners using hormonal contraceptives must also use an additional approved method of contraception. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation.
排除标准
- •Evidence of clinically significant cardiovascular, hepatic, GI, renal, respiratory, endocrine, hematological, neurological, or psychiatric disease or abnormalities or had a known history of any GI surgery or cholecystectomy.
- •Clinically significant illness within 8 weeks or had a clinically significant infection within 4 weeks prior to the first dose.
- •Known food allergy to any content of the standard meal to be used in this study.
- •Clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations.
- •Systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.
- •The subject has a clinically significant ECG abnormality, or had a family history of prolonged QTc syndrome or sudden death.
- •A history of smoking or use of nicotine-containing substances within the previous 2 months.
- •A history of drug or alcohol misuse in the previous 6 months.
- •Has been diagnosed with acquired immune deficiency syndrome (AIDS) or are positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
- •Has participated in a clinical trial of other drug before screening, and the time since the last use of other study drug is less than 5 times the half- life or 4 weeks, whichever is longer, or the subject is currently enrolled in another clinical trial.
- •Has received blood or blood products within 4 weeks, or donated blood or blood products within 8 weeks.
- •Has used any over-the-counter (OTC) medications or prescription drugs within 2 weeks.
研究组 & 干预措施
Fed/Fasted
surufatinib with food on Day 1 and surufatinib without food on Day 8
干预措施: surufatinib (Drug)
Fasted/Fed
surufatinib without food on Day 1 and surufatinib with food on Day 8
干预措施: surufatinib (Drug)
结局指标
主要结局
AUC (0-t) of Surufatinib
时间窗: Up to Day 15
Pharmacokinetics of surufatinib by assessment of area under the plasma concentration time curve from zero to the last measurable concentration
AUC of Surufatinib
时间窗: Up to Day 15
Pharmacokinetics of surufatinib by assessment of area under the plasma concentration curve from zero extrapolated to infinity
Cmax of Surufatinib
时间窗: Up to Day 15
Pharmacokinetics of Surufatinib by assessment of maximum plasma Surufatinib concentration
次要结局
- Number of participants with treatment emergent adverse events as assessed by CTCAE v5.0(Up to Day 15)